[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100064694":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":17,"locations":17,"responsibleParty":37,"collaborators":17,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":17,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":17,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":17,"overallStatus":59,"whyStopped":17,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":17},{"fullName":5,"class":6},"Organon and Co","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"EZ\u002FSimva 10\u002F40 mg","EXPERIMENTAL","Ezetimibe 10 mg + Simvastatin 40 mg",[13],"Drug: ezetimibe (+) simvastatin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",null,[19],"Drug: Comparator: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","ezetimibe (+) simvastatin","Duration of Treatment: 4 years",[9],[27],"MK0653A",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":17},"Comparator: Placebo","matching Placebo",[15],[33],{"name":34,"affiliation":35,"role":36},"Medical Monitor","Merck Sharp & Dohme LLC","STUDY_DIRECTOR",{"type":38,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100064694","phase-3-an-investigational-drug-on-clinical-outcomes-in-patients-with-aortic-stenosis-narrowing-of-the-major-blood-vessel-of-the-heartmk-0653a-043-am4completed-100064694",true,"NCT00092677","An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)","A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Ezetimibe + Simvastatin on Clinical Outcomes in Patients With Aortic Stenosis","Inclusion Criteria:\n\n* Patients aged 45 to 85 with mild abnormalities of the aortic valve as confirmed by an echocardiogram.\n\nExclusion Criteria:\n\n* Patients previously in a trial using the study drug, or currently taking any medications that are not allowed in this study.",false,"ALL","45 Years","85 Years",{"count":51,"type":52},1873,"ACTUAL","INTERVENTIONAL",[55],"PHASE3","The purpose of this study is to evaluate whether treatment with an investigational drug as compared to placebo will reduce the risk of major cardiovascular events in patients with aortic stenosis.",[58],"Aortic Stenosis","COMPLETED","2024-05-08",{"date":62,"type":52},"2024-05-16",{"date":64,"type":17},"2001-01",{"date":66,"type":52},"2008-04",{"name":5,"class":6}]